Low-Dose Thrombolysis Plus Argatroban Signals Benefit in Ischemic Stroke
A retrospective cohort links adjunctive argatroban after reduced-dose thrombolysis to better early neurological recovery without excess bleeding, but the nonrandomized design confines the findings to hypothesis-generating status.
Combining tenecteplase with argatroban might enhance stroke recovery.
Intravenous thrombolysis is crucial for acute ischemic stroke management, but optimizing reperfusion while minimizing rethrombosis is challenging. Adding argatroban to low-dose tenecteplase improved early neurological outcomes and functional recovery without significantly increasing adverse events. These findings from a single-center, retrospective study are promising but require further validation through randomized controlled trials to confirm efficacy and safety. Tenecteplase plus argatroban shows potential for better outcomes in acute ischemic stroke patients.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Huang S, Wang X, Li D, Qiu X, Hong Z
Citation:Huang S, Wang X, Li D, et al. Clinical efficacy and safety of tenecteplase combined with argatroban for acute ischemic stroke: A single-center retrospective cohort study. Medicine. 2026;105(29):e49809. doi:10.1097/MD.0000000000049809